Review
doi: 10.1002/cld.709.
eCollection 2018 Apr.
Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis
Affiliations
- PMID: 30992796
- PMCID: PMC6385948
- DOI: 10.1002/cld.709
Item in Clipboard
Review
Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis
Clin Liver Dis (Hoboken).
.
Free PMC article
No abstract available
Figures
Current and emerging therapies for NASH. Multiple molecular pathways are involved in NASH pathogenesis Anti‐NASH strategies are shown according to their mechanism of action. Green color indicates agonist; red color indicates antagonist. Abbreviations: CTGF, connective tissue growth factor; FGF19, fibrosis growth factor 19; IBAT, ileal bile acid transporter; LPS, lipopolysaccharide; PDE, phosphodiesterase.
Similar articles
-
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5. Mol Aspects Med. 2017. PMID: 28442273 Free PMC article. Review.
-
IL6R Gene Polymorphic Variant rs2228145(C >A) as a Marker of Genetic Liability to Nonalcoholic Steatohepatitis in the Russian Population of Karelia.Bull Exp Biol Med. 2018 May;165(1):64-68. doi: 10.1007/s10517-018-4100-3. Epub 2018 May 24. Bull Exp Biol Med. 2018. PMID: 29797122
-
Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences.Cell Mol Gastroenterol Hepatol. 2015 Jun 3;1(4):356-367. doi: 10.1016/j.jcmgh.2015.05.006. eCollection 2015 Jul. Cell Mol Gastroenterol Hepatol. 2015. PMID: 28210688 Free PMC article. Review.
-
Serum ubiquitin levels in patients with nonalcoholic steatohepatitis.Hepatogastroenterology. 2003 May-Jun;50(51):738-41. Hepatogastroenterology. 2003. PMID: 12828075
-
Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.BMC Gastroenterol. 2005 Nov 11;5:35. doi: 10.1186/1471-230X-5-35. BMC Gastroenterol. 2005. PMID: 16283935 Free PMC article.
Cited by
-
Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine.Front Endocrinol (Lausanne). 2021 Mar 18;12:601160. doi: 10.3389/fendo.2021.601160. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815271 Free PMC article.
-
Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.Front Endocrinol (Lausanne). 2020 Dec 23;11:592373. doi: 10.3389/fendo.2020.592373. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33424768 Free PMC article. Review.
-
New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease.Cells. 2019 Sep 10;8(9):1062. doi: 10.3390/cells8091062. Cells. 2019. PMID: 31510105 Free PMC article.
-
A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).Adv Ther. 2019 Jul;36(7):1574-1594. doi: 10.1007/s12325-019-00960-3. Epub 2019 May 7. Adv Ther. 2019. PMID: 31065991 Free PMC article. Review.
References
-
- Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology 2015;61:1547‐1554. - PubMed
-
- Marra F, Svegliati‐Baroni G. Lipotoxicity and the gut‐liver axis in NASH pathogenesis. J Hepatol 2018;68:280‐295. - PubMed
-
- Safadi R, Konikoff FM, Mahamid M, Zelber‐Sagi S, Halpern M, Gilat T, et al. The fatty acid‐bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2085‐2091.e1. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
